BRAF and cancer: It is noteworthy that the cohort validation results further confirmed the correlation between the high mutation rate of BRAF and pathogenicity, suggesting that BRAF mutation may be a valuable marker of PTCs and is significantly associated with the metastasis, prognosis, and increased cancer-related mortality of PTCs 30-32.